ALM Almirall, S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Almirall (BME: ALM)
›
Almirall (BME: ALM) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,108 employees.
The shares were at 10.18 EUR on 19 November 2026, down 18.7% over 52 weeks. Its 52-week range is 9.810 EUR to 13.98 EUR: the price is 27.2% below the high and 3.8% above the low.
At a market capitalisation of 2.22B EUR, it trades at 29.9 times trailing earnings and 19.5 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 21% for ALM. It pays a dividend yielding 1.81% (it pays out 67% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Almirall reports return on equity of 3.1%, an operating margin of 9.6% and revenue up 9.8% year over year.
It holds more cash than debt, a net cash position of 113.70M EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 14.31 EUR is 40.6% above the current price. The next earnings report is expected on 22 February 2027.